Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (06/16/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview for Childhood Non-Hodgkin Lymphoma (NHL)

Added Special Considerations for the Treatment of Children With Cancer as a new subsection.

Mature B-cell NHL

Revised text to state that for recurrent or refractory B-lineage NHL, survival is generally 10% to 30% (cited Jourdain et al. as reference 29).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Rare NHL Occurring in Children

Next section >
About This PDQ Summary